Taiwan-based EirGenix, Inc. and Sandoz recently announced that they have entered into an agreement, giving Sandoz an exclusive license to commercialize EirGenix’s proposed biosimilar version of Roche’s Herceptin (trastuzumab), which is now in in Phase III clinical development for treatment of human epidermal growth factor receptor 2 positive (HER2+) breast and specific gastric cancer tumors. The companies’ respective press releases state that under the agreement, EirGenix will remain responsible for the development and manufacturing of its biosimilar, while Sandoz has the right to commercialize the product in all markets, except China and Taiwan, upon approval. Moreover, EirGenix states that it will receive an upfront payment on signing and milestone payments, and is entitled to receive profit share payments for sales in the territories.
The post Taiwan-based EirGenix and Sandoz Partner to Commercialize EirGenix’s Trastuzumab Biosimilar appeared first on Big Molecule Watch.